An interventional study of Ergospirometry in Breast Cancer and Germ Cell Tumor, sponsored by Jules Bordet Institute. Terminated at 1 site in Belgium. Open to participants aged 18 Years to 39 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Jules Bordet Institute · Not applicable, Interventional, and Supportive care
Poor Accrual
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Breast Neoplasms by Jules Bordet Institute — 7 open to participants now, 9 under way, none of them phase 3. Breast Neoplasms · Jules Bordet Institute.
Among the 42 studies in Breast Neoplasms by Jules Bordet Institute, this one is the 31st largest by enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2022, is one of 6 with no phase, and was the 36th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →7 of the 42 studies in Breast Neoplasms by Jules Bordet Institute are open now, in 10 countries. Recruiting first, the newest first:
Jules Bordet Institute · Sites in Belgium
Ages 18+ · Women only
Jules Bordet Institute · Sites in Belgium
Ages 18–70 · Women only
Jules Bordet Institute · Sites in Belgium
Ages 18+ · Women only
Jules Bordet Institute · Sites in Belgium, Germany, Iceland and 7 more countries
Ages 18+
Jules Bordet Institute
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 39 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 27 · Phase 3 1
First in 2003; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 49 across the 38 interventional studies, 1,200 across the 4 observational. Of the 23 that completed or were terminated, 2 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
Jules Bordet Institute is the lead sponsor of 106 studies on the registry; 27 are open to participants now.
1 of the studies in Breast Neoplasms by Jules Bordet Institute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06150898Jules Bordet InstituteKetorolac and Pregabalin Effects on breaSt Cancer (KePreSt) | 2027-04-20 |
Add it to your calendar (.ics) → With an account.
Among the 42 studies in Breast Neoplasms by Jules Bordet Institute, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prospective longitudinal, single-center, non-randomized study for the implementation of an integrated multidisciplinary fatigue follow-up for young patients with breast cancer or germ cell tumour
Each patient will receive a full evaluation by a multidisciplinary evaluation by a multidisciplinary team during one day. This evaluation will take place between 1 and 3 months after the end of "acute" treatments. The team is composed of an oncologist, a psychologist, a physiotherapist, a dietician and a nurse-coach. The goal of this comprehensive evaluation is to :
This plan will be explained in detail to the patient by the nurse-coach who will organize and coordinate the patient's care. The patient will receive the detailed management plan in writing.
The patient will receive the detailed management plan in writing, which will also be communicated to the patient's treating physicians.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Ergospirometry
Maximum aerobic capacity (VO2 max), Maximum load, Ventilatory threshold and the patient's RQ
Evaluate the feasibility of the specific fatigue management program
Rate of participation The program will be considered feasible for a given patient if he/she participates in a minimum of 70% of the 70% of the sessions/activities defined in their particular program
Time frame: Through study completion, an average of 4 years
The measurement of the evolution of the intensity of residual fatigue in the months following acute cancer treatment(s) before and after the specific fatigue management program
Numerical Rating Scale (NRS) for fatigue
Time frame: At the time of multidisciplinary screening and at 1, 3, 6, 12 and 18 months after completion of the specific fatigue management program.
Ran from Aug 2022 to primary completion in Nov 2025, 39 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Sep 2026 → Nov 2025 and completion Sep 2027 → Nov 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Poor Accrual
Poor Accrual
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.